![fac-[Re(CO)3(L3)(H2O)][NO3]](https://file.medchemexpress.com/product_pic/hy-155719.gif "Click to View fac-[Re(CO)3(L3)(H2O)][NO3] Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
373 Results for "
Complex I
" in MedChemExpress (MCE) Product Catalog:
Products (373)
373 Results for "Complex I" in MCE Product Catalog:
Cat. No.: HY-155719
Target:
Research Areas:
fac-[Re(CO)3(L3)(H2O)][NO3] (compound 3), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L3)(H2O)][NO3] is cytotoxic to prostate cancer cells with IC50=0.32 μM (PC-3 cells). fac-[Re(CO)3(L3)(H2O)][NO3] mainly accumulates in mitochondria, down-regulates ATP production in PC3 cells, and promotes paraptosis. However, fac-[Re(CO)3(L3)(H2O)][NO3] did not induce necrosis, apoptosis and autophagy .
Cat. No.: HY-174252
CAS No.: 3016396-78-1
Target:
Research Areas:
HSV-1/HSV-2-IN-3 inhibits the herpes-simplex-virus (HSV) helicase-primase complex, blocking the coordinated DNA-unwinding and primer-synthesis steps required for viral genome replication. HSV-1/HSV-2-IN-3 exhibits an EC50 of 7.0 nM against HSV-2 in a gD-immunofluorescence cell assay containing 2 % FBS and 57.5 nM when 10 % human serum is present. HSV-1/HSV-2-IN-3 achieves an EC50 of 1.1 nM in a qPCR replication assay. HSV-1/HSV-2-IN-3 shows strong selectivity over human carbonic-anhydrase off-targets (IC50 ≈ 2.9 µM for hCA II and > 35 µM for hCA I). HSV-1/HSV-2-IN-3 can be studied in anti-HSV research .
Cat. No.: HY-P5832
CAS No.: 836606-84-9
Target:
Research Areas:
Cat. No.: HY-126051
CAS No.: 1381782-08-6
Synonyms: (-)-Viriditoxin
Category:
Cat. No.: HY-13323R
CAS No.: 1138549-36-6
Target:
Reference Standards DNA/RNA Synthesis MDM-2/p53 AMPK Akt Autophagy Apoptosis Checkpoint Kinase (Chk)
Research Areas:
CX-5461 (Standard) is the analytical standard of CX-5461 (HY-13323). This product is intended for research and analytical applications. CX-5461 is a selective, orally active RNA polymerase I inhibitor. CX-5461 disrupts the formation of the SL1-rDNA complex, thereby blocking the transcription initiation of ribosomal RNA without altering the activity of RNA polymerase II, DNA replication, or protein translation processes. CX-5461 upregulates the expression of p21, MDM2, Sestrin1/2, and phosphorylated AMPKα, and reduces the level of phosphorylated Akt. CX-5461 induces G2/G2/M cell cycle arrest, Autophagy, Apoptosis, and cellular senescence, and activates CHK1, CHK2, and RPA. CX-5461 can be used in research related to osteosarcoma, cervical cancer, hematologic malignancies, high-grade serous ovarian cancer, and solid tumors .
Synonyms: (1S,9R)-DX8951f
Target:
Research Areas:
(1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative and a topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1S,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1S,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1S,9R)-Exatecan mesylate is widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia .
The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).
The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).
NRX-0492 is an orally active BTK PROTAC degrader, with a binding IC50 of 1.2 nM for both wild-type BTK and BTK T474I, and 2.7 nM for BTK C481S, and exhibits cellular DC50 values of 0.1 nM and 0.2 nM against wild-type BTK and BTK C481S, respectively. NRX-0492 catalyzes the ubiquitination and proteasomal degradation of wild-type and drug-resistant mutant BTK by recruiting the CRBN E3 ubiquitin ligase complex. NRX-0492 inhibits the BCR signaling pathway and its downstream NF-κB/MYC transcriptional program, achieves rapid and sustained degradation in primary CLL cells, and exhibits extremely low cytotoxicity. NRX-0492 degrades BTK, inhibits tumor cell proliferation and activation, and significantly suppresses tumor growth in xenograft models. NRX-0492 can be used in research related to chronic lymphocytic leukemia and diffuse large B-cell lymphoma .
Cat. No.: HY-N10508
CAS No.: 71204-89-2
Target:
Cat. No.: HY-P72368
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: FCGRT; Major Histocompatibility Complex Class I-Like Fc Receptor; Fc Gamma Receptor And Transporter; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 6; Neonatal Fc Receptor; Neonatal Crystallizable Fc Receptor FcRn Splice Variant 5; FcRn; Neonatal Fragment Crystallizable Fc Receptor FcRn; IgG Fc Fragment Receptor Transporter Alpha Chain; Immunoglobulin Receptor, Intestinal, Heavy Chain; IgG Receptor FcRn Large Subunit P51; Neonatal Fc-Receptor For Ig; FcgammaRn; FCRN Alpha-Chain; Heavy Chain Of The Major Histocompatibility Complex Class I-Like Fc Receptor; FcRn Alpha Chain; Transmembrane Alpha Chain Of The Neonatal Receptor; Alpha-Chain; Fc Fragment Of IgG, Receptor, Transporter, Alpha; FCRN; Fc Fragment Of IgG Receptor And Transporter; B2M; Beta 2-Microglobulin; Beta-2-Microglobulin; Beta-2-Microglobin; Beta Chain Of MHC Class I Molecules; AMYLD6; Beta 2-Microglobulin Protein; MHC1D4; Human Nkt Tcr Alpha Chain; IMD43; Human Nkt Tcr Beta Chain
Species:
Human
Source:
HEK293
Cat. No.: HY-N10508S
CAS No.: 1637678-42-2
Cat. No.: HY-N8693
CAS No.: 362472-81-9
Category:
Cat. No.: HY-170524
CAS No.: 3052313-73-9
Research Areas:
TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
Cat. No.: HY-P86979
Synonyms: 2810406C15Rik antibody; 2810465G24Rik antibody; CAP-D2 antibody; CAPD2 antibody; CEP2 antibody; CEP250 antibody; Chromosome condensation-related SMC-associated protein 1 antibody; Chromosome-associated protein D2 antibody; CNAP1 antibody; CND1 antibody; 2810406C15Rik antibody; 2810465G24Rik antibody; CAP-D2 antibody; CAPD2 antibody; CEP2 antibody; CEP250 antibody; Chromosome condensation-related SMC-associated protein 1 antibody; Chromosome-associated protein D2 antibody; CNAP1 antibody; CND1 antibody; Condensin antibody; Condensin Complex subunit 1 antibody; eg7 antibody; hCAP-D2 antibody; hCAPD2 antibody; KIAA0159 antibody; mKIAA0159 antibody; NCAPD2 antibody; non-SMC condensin I Complex, subunit D2 antibody; XCAP D2 homolog antibody;
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
